Patents by Inventor Jerome Molette

Jerome Molette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11306089
    Abstract: The present invention relates to novel compounds of the formula (II) and formula (III) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: April 19, 2022
    Assignee: LIFE MOLECULAR IMAGING LIMITED
    Inventors: Mathias Berndt, Andre Müller, Felix Oden, Hanno Schieferstein, Heribert Schmitt-Willich, Heiko Kroth, Jérôme Molette
  • Publication number: 20210267989
    Abstract: The present invention relates to novel compounds of formula (I) that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).
    Type: Application
    Filed: May 30, 2019
    Publication date: September 2, 2021
    Inventors: Sreenivasachary Nampally, Emanuele Gabellieri, Jerome Molette
  • Publication number: 20210252175
    Abstract: The present invention relates to novel compounds that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity of a group of disorders and abnormalities associated with alpha-synuclein (?-synuclein, A-synuclein, aSynuclein, a-synuclein, A-syn, ?-syn, aSyn, SNCA, Non-amyloid beta component of Alzheimer's disease (AD) amyloid plaques, Non-A4 component of amyloid precursor, NACP) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease (PD). The instant compounds are particularly useful in the diagnosis of the preclinical state of such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament.
    Type: Application
    Filed: June 7, 2019
    Publication date: August 19, 2021
    Inventor: Jérôme MOLETTE
  • Publication number: 20210214371
    Abstract: The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).
    Type: Application
    Filed: May 20, 2019
    Publication date: July 15, 2021
    Inventors: Sreenivasachary Nampally, Emanuele Gabellieri, Jerome Molette, Heiko Kroth, Cedric Boudou
  • Publication number: 20210047321
    Abstract: The present invention relates to novel compounds of the formula (II) and formula (III) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
    Type: Application
    Filed: January 22, 2019
    Publication date: February 18, 2021
    Inventors: Mathias BERNDT, Andre MÜLLER, Felix ODEN, Hanno SCHIEFERSTEIN, Heribert SCHMITT-WILLICH, Heiko KROTH, Jérôme MOLETTE
  • Publication number: 20210047327
    Abstract: The present application relates to a diagnostic composition comprising: a. a compound of Formula I, b. ethanol, c. water, and d. a hydroxycarboxylic acid, a salt of a hydroxycarboxylic acid or a mixture thereof. The diagnostic composition can be used in the selective detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease (AD) and other tauopathies, for example, using Positron Emission Tomography (PET). The present invention also relates to a method of preparing the claimed diagnostic composition.
    Type: Application
    Filed: January 22, 2019
    Publication date: February 18, 2021
    Inventors: Johnny CASTILLO MELEAN, Thomas BETZEL, Mathias BERNDT, Hanno SCHIEFERSTEIN, Heiko KROTH, Jérôme MOLETTE, Vincent DARMENCY, Emanuele GABELLIERI
  • Publication number: 20210038747
    Abstract: The present invention relates to a novel method of preparing a compound of the formula I. Diagnostic compositions and their use in the selective detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease (AD) and other tauopathies, for example, using Positron Emission Tomography (PET) imaging are also disclosed.
    Type: Application
    Filed: January 22, 2019
    Publication date: February 11, 2021
    Inventors: Marion ZERNA, Mathias BERNDT, Hanno SCHIEFERSTEIN, Johnny CASTILLO MELEAN, Heiko KROTH, Jérôme MOLETTE, Vincent DARMENCY, Emanuele GABELLIERI
  • Publication number: 20210041447
    Abstract: The present invention relates to novel compounds of the formula (II) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging. The present invention also discloses intermediates which are useful in the preparation of these compounds.
    Type: Application
    Filed: January 22, 2019
    Publication date: February 11, 2021
    Inventors: Mathias BERNDT, Andre MÜLLER, Felix ODEN, Hanno SCHIEFERSTEIN, Heribert SCHMITT-WILLICH, Heiko KROTH, Jérôme MOLETTE, Emanuele GABELLIERI, Cédric BOUDOU
  • Patent number: 10865207
    Abstract: The present invention relates to novel compounds of the formula (I) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: December 15, 2020
    Assignees: AC IMMUNE S.A., LIFE MOLECULAR IMAGING SA
    Inventors: Heiko Kroth, Jérôme Molette, Hanno Schieferstein, Andre Müller, Heribert Schmitt-Willich, Mathias Berndt, Felix Oden
  • Patent number: 10835624
    Abstract: The present invention relates to novel compounds of the formula (II) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: November 17, 2020
    Assignees: AC IMMUNE S.A., LIFE MOLECULAR IMAGING SA
    Inventors: Heiko Kroth, Jérôme Molette, Vincent Darmency, Hanno Schieferstein, Andre Müller, Heribert Schmitt-Willich, Mathias Berndt, Felix Oden, Emanuele Gabellieri
  • Publication number: 20200299305
    Abstract: The present invention relates to novel compounds that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity, of a group of disorders and abnormalities associated with alpha-synuclein (?-synuclein, A-synuclein, aSynuclein, A-syn, ?-syn, aSyn) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease. The instant compounds are particularly useful in determining a predisposition to such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament. The present compounds can also be used to treat, alleviate or prevent a disorder or abnormality associated with alpha-synuclein aggregates.
    Type: Application
    Filed: June 5, 2020
    Publication date: September 24, 2020
    Inventors: Jérôme Molette, Emanuele Gabellieri, Vincent Darmency
  • Publication number: 20200148679
    Abstract: The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).
    Type: Application
    Filed: January 9, 2020
    Publication date: May 14, 2020
    Inventors: Sreenivasachary NAMPALLY, Emanuele GABELLIERI, Jerome MOLETTE
  • Publication number: 20190263817
    Abstract: The present invention relates to novel compounds of the formula (I) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
    Type: Application
    Filed: July 21, 2017
    Publication date: August 29, 2019
    Inventors: Heiko KROTH, Jerome MOLETTE, Hanno SCHIEFERSTEIN, Andre MULLER, Heribert SCHMITT-WILLICH, Mathias BERNDT, Felix ODEN
  • Publication number: 20190262480
    Abstract: The present invention relates to novel compounds of the formula (II) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
    Type: Application
    Filed: July 21, 2017
    Publication date: August 29, 2019
    Inventors: Heiko KROTH, Jérôme MOLETTE, Vicent DARMENCY, Hanno SCHIEFERSTEIN, Andre MÜLLER, Heribert SCHMITT-WILLICH, Mathias BERNDT, Felix ODEN, Emanuele GABELLIERI
  • Publication number: 20190211012
    Abstract: The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).
    Type: Application
    Filed: March 13, 2019
    Publication date: July 11, 2019
    Inventors: Sreenivasachary NAMPALLY, Emanuele GABELLIERI, Jerome MOLETTE
  • Publication number: 20190071450
    Abstract: The present invention relates to novel compounds that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity, of a group of disorders and abnormalities associated with alpha-synuclein (?-synuclein, A-synuclein, aSynuclein, A-syn, ?-syn, aSyn) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease. The instant compounds are particularly useful in determining a predisposition to such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament. The present compounds can also be used to treat, alleviate or prevent a disorder or abnormality associated with alpha-synuclein aggregates.
    Type: Application
    Filed: March 10, 2017
    Publication date: March 7, 2019
    Inventors: Jérôme MOLETTE, Emanuele GABELLIERI, Vincent DARMENCY
  • Publication number: 20180273476
    Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Application
    Filed: January 22, 2018
    Publication date: September 27, 2018
    Inventors: Andrew Harvey, Agnes Bombrun, Rachel Cooke, Isabelle Jeanclaude-Etter, Nathan Kuchel, Jerome Molette, Jorgen Mould, Dharam Paul, Rajinder Singh, Cristina Donini, Veronique Colovray, Thomas Avery, Julia Crossman, Justin Ripper
  • Publication number: 20180264146
    Abstract: The present invention relates to novel compounds that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
    Type: Application
    Filed: July 15, 2016
    Publication date: September 20, 2018
    Applicants: AC IMMUNE S.A., PIRAMAL IMAGING SA
    Inventors: Heiko KROTH, Sreenivasachary NAMPALLY, Jérôme MOLETTE, Emanuele GABELLIERI, Hanno SCHIEFERSTEIN, Andre MÜLLER, Heribert SCHMITT-WILLICH, Mathias BERNDT
  • Patent number: 9914702
    Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: March 13, 2018
    Assignees: Bionomics Limited, Merck Patent GmbH
    Inventors: Andrew Harvey, Agnes Bombrun, Rachel Cooke, Isabelle Jeanclaude-Etter, Nathan Kuchel, Jerome Molette, Jorgen Mould, Dharam Paul, Rajinder Singh, Cristina Donini, Veronique Colovray, Thomas Avery, Julia Crossman, Justin Ripper
  • Publication number: 20170088519
    Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Application
    Filed: December 1, 2016
    Publication date: March 30, 2017
    Inventors: Andrew Harvey, Agnes Bombrun, Rachel Cooke, Isabelle Jeanclaude-Etter, Nathan Kuchel, Jerome Molette, Jorgen Mould, Dharam Paul, Rajinder Singh, Cristina Donini, Veronique Colovray, Thomas Avery, Julia Crossman, Justin Ripper